Performance of MRI-Based vs Clinical T Staging in Localized Prostate Cancer - Summary - MDSpire

Performance of MRI-Based vs Clinical T Staging in Localized Prostate Cancer

  • By

  • Arthur Peyrottes

  • Michael Baboudjian

  • Thibaut Long-Depaquit

  • Morgan Rouprêt

  • Thierry Roumeguere

  • Alexandre Peltier

  • Guillaume Ploussard

  • Romain Diamand

  • iTNM Consortium

  • Julien Anract

  • Grégoire Assenmacher

  • Francesco Barletta

  • Eric Barret

  • Edoardo Beatrici

  • Daniel Benamran

  • Vincent Benard

  • Nathan Bergier

  • Léa Bollen

  • Claudio Brancelli

  • Norbert de Brek

  • Laurent Brureau

  • Marie Chicaud

  • Mathieu Coscarella

  • Charles Dariane

  • Igor Duquesne

  • Mariaconsiglia Ferriero

  • Gaelle Fiard

  • Giorgio Gandaglia

  • Alexander Giesen

  • Ruben De Groote

  • Ruth Himmelsbach

  • Serge Holz

  • Steven Joniau

  • Marvin Jourdan

  • Romain Lefranc

  • Stéphan Lévy

  • Thibaut Long Depaquit

  • Charles Mazeaud

  • Benoit Mesnard

  • Stefano Moretto

  • Yann Neuzillet

  • Myky Nguyen

  • Marco Oderda

  • Jonathan Olivier

  • Dimitri Paillusson

  • Frédéric Panthier

  • Maxime Pattou

  • Andreas Røder

  • Maj Sanson-Stern

  • Alberto Sasia

  • Pietro Scilipoti

  • August Sigle

  • Hein Vincent Stroomberg

  • Fayek Taha

  • Gabrielle Tissot

  • Julien Van Damme

  • Thibaut Waeckel

  • Olivier Windisch

  • July 15, 2026

Share

Objective:

To evaluate the performance of MRI-based staging compared with traditional DRE-based staging in men undergoing radical prostatectomy and assess whether MRI could replace DRE staging in contemporary risk estimation models.

Approach:
  • Study Design: Multicenter, retrospective case-control study involving patients with histologically confirmed localized or locally advanced prostate cancer who underwent radical prostatectomy across 31 institutions in Europe.
  • Patient Selection: Included patients aged 18 or older who underwent preoperative multiparametric MRI and systematic biopsies, excluding those with prior therapy for prostate cancer or missing key variables.
  • Staging Comparison: Both DRE-based clinical staging and MRI-based staging were performed, allowing direct comparison of clinical T stage (cT) and MRI-derived T stage (iT).
  • Outcome Measures: Primary outcome was distant metastasis-free survival (DMFS); secondary outcomes included biochemical recurrence-free survival (BCRFS) and overall survival (OS).
Key Findings:
  • MRI may upstage a substantial proportion of patients compared with DRE.
  • The impact of MRI-derived staging on clinically relevant outcomes remains unclear.
  • Prior studies on this topic have limitations such as small sample sizes and lack of long-term follow-up.
Interpretation:

Limitations:
  • Retrospective design may introduce bias.
  • Limited long-term follow-up data.
  • Potential variability in MRI interpretation across centers.
Conclusion:

The study seeks to provide insights into the comparative effectiveness of MRI and DRE in staging localized prostate cancer.

Original Source(s)

Performance of MRI-Based vs Clinical T Staging in Localized Prostate Cancer

  • by Arthur Peyrottes, Michael Baboudjian, Thibaut Long-Depaquit, Morgan Rouprêt, Thierry Roumeguere, Alexandre Peltier, Guillaume Ploussard, Romain Diamand, iTNM Consortium, Julien Anract, Grégoire Assenmacher, Francesco Barletta, Eric Barret, Edoardo Beatrici, Daniel Benamran, Vincent Benard, Nathan Bergier, Léa Bollen, Claudio Brancelli, Norbert de Brek, Laurent Brureau, Marie Chicaud, Mathieu Coscarella, Charles Dariane, Igor Duquesne, Mariaconsiglia Ferriero, Gaelle Fiard, Giorgio Gandaglia, Alexander Giesen, Ruben De Groote, Ruth Himmelsbach, Serge Holz, Steven Joniau, Marvin Jourdan, Romain Lefranc, Stéphan Lévy, Thibaut Long Depaquit, Charles Mazeaud, Benoit Mesnard, Stefano Moretto, Yann Neuzillet, Myky Nguyen, Marco Oderda, Jonathan Olivier, Dimitri Paillusson, Frédéric Panthier, Maxime Pattou, Andreas Røder, Maj Sanson-Stern, Alberto Sasia, Pietro Scilipoti, August Sigle, Hein Vincent Stroomberg, Fayek Taha, Gabrielle Tissot, Julien Van Damme, Thibaut Waeckel, Olivier Windisch

  • July 15, 2026

Related Content

Immunological barriers and engineering strategies for CAR-T cell therapy in acute myeloid leukemia

Results of applying the 9th edition TNM classification in the staging assessment of nasopharyngeal carcinoma: first data in Vietnam

Spatial associations between esophageal lesions and surrounding tissues in esophageal fistula: a CAM-guided radiomics study